Amgen Says FDA Approves Kyprolis Combination to Treat Multiple Myeloma
December 01 2021 - 02:27PM
Dow Jones News
By Stephen Nakrosis
Amgen Inc. said Wednesday the U.S. Food and Drug Administration
approved Kyprolis in a combination regime to treat certain adult
patients with relapsed or refractory multiple myeloma.
The company said the FDA expanded Kyprolis' prescribing
information to include its use with Darzalex Faspro, or daratumumab
and hyaluronidase-fihj, and dexamethasone to treat adults with
relapsed or refractory multiple myeloma who have received one to
three lines of therapy.
Amgen said the expansion was supported by an ongoing Phase 2
trial evaluating Darzalex Faspro in combination with four
standard-of-care treatment regimens in patients with multiple
myeloma.
At 1:50 p.m. ET, Amgen shares were trading 2.4% higher at
$203.59.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 01, 2021 14:12 ET (19:12 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Mar 2023 to Mar 2024